Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results
Press Release – No. 14 / 2023
Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results
Copenhagen, Denmark, November 3, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on November 9, 2023, at 2:00 pm CET (8:00 am ET) following the announcement of results for the third quarter and first nine months of 2023.
Presenting during the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David Kendall. The presentation will be followed by a Q&A session, and both will be conducted in English.
Telephone dial-in information and a unique personal access PIN will be provided upon registration at https://register.vevent.com/register/BId73e050fc44d47be81015697a873e070.
A live audio webcast of the conference call and accompanying slide presentation will be available at https://edge.media-server.com/mmc/p/b9gpnynv and accessible through the company’s website at www.zealandpharma.com/events-cal where a recording of the webcast will also be archived after the event.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development and partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.
Contacts:
| Adam Lange (Investors) |
| Investor Relations Officer |
| Zealand Pharma |
| akl@zealandpharma.com |
| Anna Krassowska, PhD (Investors and Media) |
| Vice President, Investor Relations & Corporate Communications |
| Zealand Pharma |
| ank@zealandpharma.com |
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Forventede udbytter for regnskabsåret 202311.12.2023 10:46:46 CET | pressemeddelelse
Investeringsforeningen C WorldWide har nu opgjort de forventede udbytter (angivet i kr. pr. andel), som fremgår nedenfor. Dette er foreløbige beløb, og disse kan således ændre sig, f.eks. ved handelsaktivitet m.m. i den resterende del af året kan påvirke de estimerede udlodninger i såvel opadgående som nedadgående retning. Foreningen forventer at udbyttet har ex. dag den 23. januar 2024 med udbetaling den 25. januar 2024. Foreningen offentliggør de endelige udbyttesatser ca. medio januar 2024. De forventede udbytter er opgjort til: ISIN Afdeling kr. pr. andel DK0010157965 Globale Aktier KL A 75,70 DK0010312529 Stabile Aktier KL A 0,00 DK0060057644 Asien KL A 0,00 DK0015945166 Emerging Markets KL A 0,00 DK0061534963 Indien KL A 0,00 DK0060287217 Globale Aktier Etik KL Udl 11,20 Med venlig hilsen C WorldWide Fund Management, filial af C WorldWide Fund Management S.A., Luxembourg Henrik Brandt Direktør Vedhæftet fil 2023.12.11 Forventet udlodning 2023
SKEL fjárfestingafélag hf: Buy-back Programme week 4911.12.2023 10:44:04 CET | Press release
In week 49 2023, SKEL fjárfestingafélag hf. purchased in total 1,800,000 own shares for total amount of 23,165,000 ISK as follows: DateTimePurchased sharesPricePurchase priceTotal own shares4.12.202309:50:00500,000 12.46,200,000 51.792.855 5.12.202313:37:00500,000 12.66.300,000 52.292.855 6.12.202314:06:00550,000 13.37,315,000 52.842.855 7.12.202309:31:00250,000 13.43.350,000 53.092.855 1,800,00023,165,00053,092,855 The execution of the buy-back programme is in accordance with Chapter VIII of the Company Act No 2/1995, Article 5 of the Regulation of the European parliament and of the Council (EU) on Market Fraud No. 60/2021, the Commissions Delegated Regulation No. 2016/1052 and the Act on Actions against Market Fraud No. 60/2021. Before the purchase SKEL held 51,292,855 own shares. SKEL fjárfestingafélag hf. bought in total 34,574,337 own shares, which corresponds to 17.86% of maximum number of shares that will be purchased according to the current buy-back programme. The purchase pri
Transactions in connection with share buy-back program11.12.2023 10:43:02 CET | Press release
Announcement A.P. Møller - Mærsk A/S – Transactions in connection with share buy-back program On 5 May 2021, A.P. Møller - Mærsk A/S (the “Company”) announced a share buy-back program of up to DKK 32bn (around USD 5bn) to be executed over a period of two years. On 2 November 2021, the Company decided to extend the current share buy-back program by additionally DKK 32 billion (around USD 5 billion) during 2024 and 2025 bringing the total program up to DKK 64 billion (around USD 10 billion). On 12 August 2022 the Company announced an increase of the share buy-back program up to DKK 84 billion (around USD 12 billion). As announced on 3 November 2023, during the fifth phase of the program running from 6 November 2023 up to 1 May 2024, the Company will buy back A and B shares for an amount of up to DKK 11bn. The fifth phase of the share buy-back program will be executed under EU Commission Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commissi
Transaktioner i henhold til aktietilbagekøbsprogram11.12.2023 10:43:02 CET | pressemeddelelse
SELSKABSMEDDELELSE A.P. Møller - Mærsk A/S – Transaktioner i henhold til aktietilbagekøbsprogram Den 5. maj 2021 annoncerede A.P. Møller - Mærsk A/S (“Selskabet”) et aktietilbagekøbsprogram til en værdi af op til DKK 32 mia. (ca. USD 5 mia.), der vil blive opkøbt over en periode på op til to år. Den 2. november 2021 besluttede Selskabet at forøge det nuværende aktietilbagekøbsprogram med yderligere DKK 32 mia. (ca. USD 5 mia.) i løbet af 2024 og 2025, hvilket bringer det samlede program op til i alt DKK 64 mia. (ca. USD 10 mia.). Den 12. august 2022 offentliggjorde Selskabet en forøgelse af aktietilbagekøbsprogrammet op til DKK 84 mia. (ca. USD 6 mia.). Som annonceret den 6. november 2023, vil Selskabet i femte fase af programmet, der løber fra 3. november 2023 til 1. maj 2024, købe egne A-aktier og B-aktier for et beløb op til DKK 11 mia. Femte fase af tilbagekøbsprogrammet gennemføres i overensstemmelse med EU Kommissionens forordning nr. 596/2014 af 16. april 2014 (MAR) og EU Kommis
Notification of managers and closely related parties’ transactions with A.P. Møller - Mærsk A/S shares in connection with share buy-back program11.12.2023 10:28:17 CET | Press release
In connection with the announced share buy-back program in A.P. Møller - Mærsk A/S, A.P. Møller Holding A/S continuously sells shares pro rata and the market is to be informed accordingly – see the attached file. Attachment APMM Share buy-back APMH sale 08122023